Evidence sheet · an FDA decision

INO-3107

Inovio · Recurrent respiratory papillomatosis

INO-3107 goes before the FDA on 30 October 2026. The record holds three FDA events for it, all dated 29 December 2025: one against the filing, one in its favour and one that counts neither way.

Standing: concern recorded. Our signed call: below average.

A model portfolio kept for research. It is not an offer, a solicitation or a recommendation to buy or sell any security, and it is not personal advice. The calls are on how the FDA is likely to decide, read from the FDA's own register. The potential return on the first screen combines them with the major banks' targets and each company's cash; it illustrates the room's inputs and is not a forecast of any share price. No money is invested. Past decision-day moves describe a handful of events and predict nothing.

• 29 Dec 2025FDA questioned eligibility for accelerated approval sourceagainst the filing
• 29 Dec 2025FDA not planning advisory committee sourcein its favour
• 29 Dec 2025INO-3107 BLA accepted, standard review sourcecounts neither way
• 30 Oct 2026FDA decision due

The evidence it is filed on

• INO-3107 phase 1/2 study in RRP source

The company behind it: Inovio

Political connections

• Lobbying. No lobbying filed under its own name in the record.
• Groups it is listed in. California Life Sciences source; Life Sciences Pennsylvania source.
• Political committees. INOVIO PHARMACEUTICALS, INC. DNA MEDICINES POLITICAL ACTION COMMITTEE source.

Directors and officers, 11

• Simon X. Benito sourcedirector
• Peter Kies sourceexecutive officer
• Roger D. Dansey, M.D. sourcedirector
• Ann C. Miller, M.D. sourcedirector
• Michael Sumner, M.D. sourceexecutive officer
• Jacqueline E. Shea, Ph.D. sourcedirector and executive officer
• David B. Weiner, Ph.D. sourcedirector
• Laurent M. Humeau, Ph.D. sourceexecutive officer
• Jay P. Shepard sourcedirector
• Wendy L. Yarno sourcedirector
• Lota S. Zoth sourcedirector

Largest holders

• Listed as holding 5% or more, per the company's own ownership table. Alyeska Investment Group, L.P. source; FMR LLC source; Janus Henderson Group plc source.
• Five largest on Form 13F. ADAR1 Capital Management, LLC source; Boxer Capital Management, LLC source; FMR LLC source; Jupiter Topco LLC source; VANGUARD CAPITAL MANAGEMENT LLC source.